SG11202009759SA - Compositions and methods for treating macular dystrophy - Google Patents

Compositions and methods for treating macular dystrophy

Info

Publication number
SG11202009759SA
SG11202009759SA SG11202009759SA SG11202009759SA SG11202009759SA SG 11202009759S A SG11202009759S A SG 11202009759SA SG 11202009759S A SG11202009759S A SG 11202009759SA SG 11202009759S A SG11202009759S A SG 11202009759SA SG 11202009759S A SG11202009759S A SG 11202009759SA
Authority
SG
Singapore
Prior art keywords
compositions
methods
macular dystrophy
treating macular
treating
Prior art date
Application number
SG11202009759SA
Other languages
English (en)
Inventor
De La Camara Cristina Martinez-Fernandez
Robert Maclaren
Gregory S Robinson
Original Assignee
Univ Oxford Innovation Ltd
Nightstarx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oxford Innovation Ltd, Nightstarx Ltd filed Critical Univ Oxford Innovation Ltd
Publication of SG11202009759SA publication Critical patent/SG11202009759SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
SG11202009759SA 2018-04-05 2019-04-05 Compositions and methods for treating macular dystrophy SG11202009759SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862653131P 2018-04-05 2018-04-05
PCT/US2019/026062 WO2019195727A1 (en) 2018-04-05 2019-04-05 Compositions and methods for treating macular dystrophy

Publications (1)

Publication Number Publication Date
SG11202009759SA true SG11202009759SA (en) 2020-10-29

Family

ID=66223872

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009759SA SG11202009759SA (en) 2018-04-05 2019-04-05 Compositions and methods for treating macular dystrophy

Country Status (21)

Country Link
US (2) US20190307900A1 (zh)
EP (1) EP3775233A1 (zh)
JP (1) JP2021520232A (zh)
KR (1) KR20210005040A (zh)
CN (1) CN113056561A (zh)
AU (1) AU2019247864A1 (zh)
BR (1) BR112020020204A2 (zh)
CA (1) CA3096088A1 (zh)
CL (1) CL2020002561A1 (zh)
CO (1) CO2020013690A2 (zh)
EA (1) EA202092069A1 (zh)
IL (1) IL277779A (zh)
JO (1) JOP20200253A1 (zh)
MA (1) MA52199A (zh)
MX (1) MX2020010477A (zh)
PE (1) PE20210918A1 (zh)
PH (1) PH12020551641A1 (zh)
RU (1) RU2020132890A (zh)
SG (1) SG11202009759SA (zh)
TW (1) TW202003052A (zh)
WO (1) WO2019195727A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019363593A1 (en) * 2018-10-25 2021-04-29 Takeda Pharmaceutical Company Limited AAV triple-plasmid system
WO2020140007A1 (en) * 2018-12-28 2020-07-02 University Of Rochester Gene therapy for best1 dominant mutations
US20230112568A1 (en) * 2020-02-28 2023-04-13 The Trustees Of The University Of Pennsylvania Treating autosomal recessive bestrophinopathies and methods for evaluating same
CN111849998A (zh) * 2020-07-29 2020-10-30 武汉纽福斯生物科技有限公司 编码人卵黄状黄斑病蛋白1的核酸分子及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2762864T3 (es) * 2008-06-18 2020-05-26 Oxford Biomedica Ltd Purificación de virus
US9163259B2 (en) * 2012-05-04 2015-10-20 Novartis Ag Viral vectors for the treatment of retinal dystrophy
CA2930282A1 (en) * 2013-11-20 2015-05-28 Fondazione Telethon Artificial dna-binding proteins and uses thereof
EP3077520A1 (en) * 2013-12-06 2016-10-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for expressing a polynucleotide of interest in the retinal pigment epithelium of a subject
GB201322798D0 (en) * 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
AU2016227668B2 (en) * 2015-03-03 2019-06-27 Fondazione Telethon Multiple vector system and uses thereof
EP3374494A4 (en) * 2015-11-11 2019-05-01 Coda Biotherapeutics, Inc. CRISPR COMPOSITIONS AND METHODS OF USE FOR GENE THERAPY

Also Published As

Publication number Publication date
PH12020551641A1 (en) 2021-07-26
BR112020020204A2 (pt) 2021-01-19
US20190307900A1 (en) 2019-10-10
JP2021520232A (ja) 2021-08-19
TW202003052A (zh) 2020-01-16
CA3096088A1 (en) 2019-10-10
PE20210918A1 (es) 2021-05-19
CN113056561A (zh) 2021-06-29
CO2020013690A2 (es) 2021-04-19
CL2020002561A1 (es) 2021-04-23
MX2020010477A (es) 2021-03-02
KR20210005040A (ko) 2021-01-13
EA202092069A1 (ru) 2021-03-12
IL277779A (en) 2020-11-30
US20230149566A1 (en) 2023-05-18
EP3775233A1 (en) 2021-02-17
AU2019247864A1 (en) 2020-10-22
MA52199A (fr) 2021-02-17
RU2020132890A (ru) 2022-05-06
JOP20200253A1 (ar) 2020-10-04
WO2019195727A1 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
IL264034A (en) Crispr/cas9-based compositions and methods for treating cancer
IL269150A (en) Preparations and methods for the treatment of cancer
IL278004A (en) Methods and preparations for treating conditions related to aging
IL277779A (en) Preparations and methods for the treatment of macular degeneration
IL274837A (en) Methods and preparations for the treatment of cancer
IL271256A (en) Preparations and methods for the treatment of teopathy
EP3458158A4 (en) COMPOSITIONS AND METHODS FOR TREATING ECZEMA
IL269157A (en) Preparations and methods for the treatment of cancer
IL285886A (en) Preparations and methods for the treatment of laminopathy
ZA202101362B (en) Compositions and methods for treating the eye
EP3697920A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION
EP3687524A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF OPHTHALMIC DISORDERS
SG11202012055PA (en) Methods and compositions for preventing or treating calciphylaxis
ZA202101342B (en) Compositions and methods for treating the eye
IL247116B (en) Compounds and methods for the treatment and prevention of macular degeneration
EP3322406A4 (en) TRANSPARENT METHODS AND COMPOSITIONS FOR THE TREATMENT OF MAMMARY DISEASES
IL272922A (en) Methods and preparations for the treatment of cone-retinal dystrophy
EP3262065A4 (en) Methods and compositions for treating dystroglycanopathy disorders
ZA202101361B (en) Compositions and methods for treating the eye
ZA202101360B (en) Compositions and methods for treating the eye
IL277463A (en) Vehicles and methods for treating itch
EP3526249A4 (en) COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING TRANSPLANT-ASSOCIATED LESION
IL272782A (en) Preparations and methods for the treatment of cancer
EP3781945A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ENDOMETRIOSIS
IL285796A (en) Methods and preparations for the treatment of cancer